Eftozanermin alfa（Cat No.:I041525）is an investigational protein therapeutic being studied for its potential in treating various cancers. It is a fusion protein that combines an engineered version of the interleukin-2 (IL-2) receptor with a cytokine, aiming to stimulate immune responses against tumors. Eftozanermin alfa works by enhancing T-cell activity and increasing the body’s natural ability to fight cancer. It is being evaluated in clinical trials, particularly for solid tumors and hematologic malignancies. This therapy represents a promising approach in immuno-oncology, designed to activate the immune system in a targeted and controlled manner.
